

ALL IMAGES VIDEOS

57,500 Results Any time

(PDF) Effective treatment of pulmonary adenocarcinoma ...

<https://www.researchgate.net/publication/327472854...>

Herein, we present a case of therapeutic efficacy of osimertinib and dabrafenib plus trametinib on a 63-year-old man with advanced lung adenocarcinoma. This patient reached a remarkable ...

Effective Treatment of Lung Adenocarcinoma Harboring EGFR ...

<https://www.sciencedirect.com/science/article/pii/S1556086420303282>

Aug 01, 2020 · Methods. In this retrospective cohort study, 15 patients with advanced lung adenocarcinoma and EGFR-activating mutation, T790M, and cis-C797S after osimertinib progression were identified by targeted next-generation sequencing. Five of these patients received a combined therapy of brigatinib and cetuximab, and 10 patients received cisplatin-based doublet chemotherapy.

Cited by: 2 Author: Yubo Wang, Nong Yang, Yongchang Zhang...
Publish Year: 2020

(PDF) The effectiveness of afatinib and osimertinib in a ...

<https://www.researchgate.net/publication/326948867...>

The effectiveness of afatinib and osimertinib in a Chinese patient with advanced lung adenocarcinoma harboring a rare triple EGFR mutation (R670W/H4835L/L833V): a case report and literature review

Search Tools

Turn off Hover Translation (关闭浮词)

ALL IMAGES VIDEOS

Add the Give with Bing extension

38,700 Results Any time

Effective Treatment of Lung Adenocarcinoma Harboring EGFR ...

https://www.sciencedirect.com/science/article/pii/S155686420303282 Aug 01, 2020 Methods. In this retrospective cohort study, 15 patients with advanced lung adenocarcinoma and EGFR-activating mutation, T790M, and cis-C797S after osimertinib progression were identified by targeted next-generation sequencing. Five of these patients received a combined therapy of brigatinib and cetuximab, and 10 patients received cisplatin-based doublet chemotherapy. Cited by: 2 Author: Yubo Wang, Nong Yang, Yongchang Zhang... Publish Year: 2020

A case of osimertinib-resistant lung adenocarcinoma ...

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312808 Abstract We report a case of initial lung adenocarcinoma in which transformation to small cell lung carcinoma (SCLC) was observed after acquired resistance to the 3rd-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib and alternating treatment between chemotherapy and osimertinib was effective. Cited by: 1 Author: Haruki Hirakawa, Kazutoshi Komiya, Chiho... Publish Year: 2018

EGFR-Mutated Lung Cancers Resistant to Osimertinib through ...

https://pubmed.ncbi.nlm.nih.gov/31377341 In addition, we retrospectively probed a case of EGFR SM lung adenocarcinoma treated with first-line osimertinib, followed by second-line erlotinib in the setting of EGFR SM/C797S. Results: Use of N-ethyl-N-nitrosourea mutagenesis against the background of EGFR L858R/C797S in conjunction with administration of gefitinib revealed preferential... Cited by: 8 Author: Deepa Rangachari, Ciric To, Jason E. Shipits... Publish Year: 2019

[Full text] Durable Clinical Response of Advanced Lung ...

https://www.dovepress.com/durable-clinical... Herein, we present a case of therapeutic efficacy of osimertinib and dabrafenib plus trametinib on a 63-year-old man with advanced lung adenocarcinoma. This patient reached a remarkable progression-free survival of 9 months without any serious adverse reaction. At the progression of the disease, C797S mutation in cis was detected by liquid biopsy. Author: Honggang Ding, Zhenjie Zhuang, Jingyi... Publish Year: 2020

Case Report: Lung Adenocarcinoma Harboring EGFR-19del ...

https://www.researchgate.net/publication/330794585... Case Report: Lung Adenocarcinoma Harboring EGFR 19del/C797S/T790M Triple Mutations Responds to Brigatinib and Anti-EGFR Antibody Combination Therapy... of 9 months in an advanced lung ...

Triple Trouble: A Case of Multiple Resistance Mechanisms ...

https://europepmc.org/articles/PMC6738260... May 01, 2019 - We report a case of a patient with EGFR-mutated lung adenocarcinoma who developed a complex resistance profile: T790M mutation, HER2 mutation and HER2 amplification after first-line EGFR-TKI. This patient was safely treated with a combination of osimertinib and trastuzumab and achieved a clinically meaningful and clear molecular response.

A case of osimertinib-resistant lung adenocarcinoma ...

atm.amegroups.com/article/view/22647/21997... Email: sueokan@cc.saga-u.ac.jp. Abstract: We report a case of initial lung adenocarcinoma in which transformation to small cell lung carcinoma (SCLC) was observed after acquired resistance to the 3rd generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib and alternating treatment between chemotherapy and osimertinib was effective.

Response to tyrosine kinase inhibitors in lung ...

https://onlinelibrary.wiley.com/doi/full/10.1111/1759-7714.13606 Osimertinib is a mutant-selective TKI approved for the treatment of T790M-positive NSCLC and has significantly greater efficacy than platinum therapy plus pemetrexed in patients with T790M-positive advanced NSCLC. A case report by Oztan et al. reported the emergence of the EGFR G724S mutation in EGFR mutant lung adenocarcinoma post...


Case Report: Osimertinib achieved remarkable and sustained ...

https://www.sciencedirect.com/science/article/pii/S0169500218303337 Jul 01, 2018 - Case Report: Osimertinib achieved remarkable and sustained disease control in an advanced non-small-cell lung cancer harboring EGFR H773L/V774M mutation complex. Author links open overlay panel Mingfei Yang a 1 Xiaofeng Tong b 1 Xiang Xu a Enkuo Zheng a Junjun Ni a Junfang Li a Juncong Yan c Yang W. Shao b d Duofang Zhao a

1 2 3 4 5 >

Search Tools

Turn off Hover Translation (关闭翻译)



Name of Journal: *World Journal of Clinical Cases*

Manuscript NO: 61429

Manuscript Type: CASE REPORT

Triple osimertinib administrations followed by chemotherapy for advanced lung adenocarcinoma : A case report

Hu XY *et al.* Successful retreatments with osimertinib for NSCLC

Xu-Yan Hu, Yu-Cheng Fei, Wen-Chao Zhou, Jin-Miao Zhu, Dong-Lai Lv

Abstract

BACKGROUND

Osimertinib is the recommended first-line treatment for adult patients with epidermal growth factor receptor (EGFR) mutation positive advanced or metastatic non-small cell lung cancer (NSCLC). However, primary or acquired resistance to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) seems inevitable, and when drug-resistance occurs

Match Overview

1	Internet 110 words crawled on 03-Nov-2020 www.sagepub.com	5%
2	Internet 69 words crawled on 15-Jun-2020 www.science.gov	3%
3	Internet 59 words crawled on 09-Nov-2018 woc2016.elsevier.com	2%
4	Crossref 39 words Hironori Yoshida, Masahiro Ooi, Young Hak Kim. "Successful Treatment with Osimertinib and Chemotherapy in a N	2%
5	Internet 29 words crawled on 07-Jul-2019 lessera.spandidos-publications.com	1%
6	Crossref 22 words Yang Gang, Yi-Long Wu, Le-Jie Cao, Jian-Hua Chen, Zhi-Yong Ma, Jiu-Wei Cui, Jie Wang, Hong-Bing Liu, Jing-Yan	1%
7	Internet 20 words crawled on 01-Aug-2020 worldofscience.org	1%
8	Internet 19 words crawled on 23-Aug-2020 www.clinicaltrials.gov	1%

国内版 国际版

Triple osimertinib administrations followed by chemotherapy for ad



ALL IMAGES VIDEOS

39,900 Results Any time ▾

A case of osimertinib-resistant lung adenocarcinoma ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312808>

Abstract We report a case of **initial lung adenocarcinoma** in which transformation to **small cell lung carcinoma (SCLC)** was observed after acquired resistance to the 3rd generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) **osimertinib** and **alternating treatment** between **chemotherapy** and **osimertinib** was effective.

Cited by: 2 Author: Haruki Hirakawa, Kazutoshi Komiya, Chi...

Publish Year: 2018

Osimertinib Administration as the Primary Epidermal Growth ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859403>

Oct 15, 2019 · We herein report a case of brain metastasis of **lung carcinoma** that was successfully managed with **osimertinib administration**. Case Report A 69-year-old woman underwent chemoradiotherapy (cisplatin + docetaxel + 60Gy radiation) prior to surgery for left upper lobe **lung adenocarcinoma**, followed by left upper lobe resection in November 2017.

Cited by: 1 Author: Susumu Noguchi, Hiroaki Kawachi, Akari...

Publish Year: 2019

Effective Treatment of Lung Adenocarcinoma Harboring ...

<https://www.sciencedirect.com/science/article/pii/S1556086420303282>

Aug 01, 2020 · Methods. In this retrospective cohort study, 15 patients with **advanced lung adenocarcinoma** and EGFR-activating mutation, T790M, and cis-C797S after **osimertinib** progression were identified by targeted next-generation sequencing. Five of these patients received a combined therapy of brigatinib and cetuximab, and 10 patients received cisplatin-based doublet **chemotherapy**.

Cited by: 2 Author: Yubo Wang, Nong Yang, Yongchang Zha...

Publish Year: 2020

Triple Trouble: A Case of Multiple Resistance Mechanisms ...

<https://europepmc.org/articles/PMC6738260>

May 01, 2019 · We report a case of a patient with EGFR-mutated **lung adenocarcinoma** who developed a complex resistance profile: T790M mutation, HER2 mutation and HER2 amplification after first-line EGFR-TKI. This patient was safely treated with a combination of **osimertinib** and trastuzumab and achieved a clinically meaningful and clear molecular response.

Cited by: 2 Author: Mike Ralki, Briqitte Maes, Karin Pat, Jok...